Mr. Huang has been Chairman of the Windtree Board of Directors since January 2019. He is currently the Founding Managing Partner to Panacea Venture. Panacea Venture is a venture capital firm that invests in early and growth stage healthcare and life sciences companies worldwide. Since 2011, Mr. Huang has served as a Managing Partner of Kleiner Perkins Caufield & Byers (KPCB) – China, focusing on the firm’s life sciences practice. Mr. Huang has made more than 15 investments in China since 2007. Prior to joining KPCB China, Mr. Huang was a Managing Partner at Vivo Ventures, a venture capital firm specializing in life sciences investments.
Prior to joining Vivo in 2007, Mr. Huang was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, Mr. Huang also held senior roles in business development, sales, marketing, and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson). Mr. Huang is Chairman of Board at Kindstar Global, JHL Biotech and XW Laboratory and Director at ChiralQuest, Zenesis, and CASI Pharmaceuticals.
Mr. Huang received an M.B.A. from the Stanford Graduate School of Business in 1992 and a B.S. degree in chemical engineering from the University of California, Berkeley.
What is James Huang's net worth?
The estimated net worth of James Huang is at least $1.41 million as of September 6th, 2022. Mr. Huang owns 335,106 shares of Windtree Therapeutics stock worth more than $1,410,796 as of May 10th. This net worth evaluation does not reflect any other assets that Mr. Huang may own. Learn More about James Huang's net worth.
How do I contact James Huang?
Has James Huang been buying or selling shares of Windtree Therapeutics?
James Huang has not been actively trading shares of Windtree Therapeutics in the last ninety days. Most recently, on Tuesday, October 19th, James Huang bought 27 shares of Windtree Therapeutics stock. The stock was acquired at an average cost of $3,420.00 per share, with a total value of $92,340.00. Learn More on James Huang's trading history.
Who are Windtree Therapeutics' active insiders?
Are insiders buying or selling shares of Windtree Therapeutics?
In the last year, Windtree Therapeutics insiders bought shares 1 times. They purchased a total of 138 shares worth more than $2,235.60. The most recent insider tranaction occured on September, 26th when CEO Craig Fraser bought 138 shares worth more than $2,235.60. Insiders at Windtree Therapeutics own 0.5% of the company.
Learn More about insider trades at Windtree Therapeutics. Information on this page was last updated on 9/26/2023.
